Combinations of immune checkpoint inhibitors with fractionated radiotherapy or DNA damage response agents leads to improved anti-tumour responses and modulates the tumour immune microenvironment.
Do you want to know how immune checkpoint inhibitors and radiotherapy and can work together to fight cancer?
In our latest poster, we explored the effects of the immune checkpoint inhibitors in combination with fractionated radiotherapy on tumour growth in a syngeneic mouse model of colorectal cancer.
We tested the combination of radiation with the immune checkpoint inhibitors PD1 and PD-L1 and found that it significantly increased therapeutic efficacy. With the use of flow cytometry, we characterised the changes in the tumour microenvironment and revealed how radiation and immunotherapy can alter the balance of the infiltrated immune cells.
Our work provides valuable insights into the mechanisms and outcomes of combining immunotherapy and radiotherapy for cancer treatment. It also offers a useful platform for testing new drugs and novel therapeutics that can potentially improve the efficacy and safety of this combination therapy.